Company

RayzeBio, Inc.

RayzeBio develops actinium-based radiopharmaceutical therapies for cancer.

About

Founded in 2020 and based in San Diego, US, RayzeBio develops targeted radiopharmaceutical therapies using actinium-225 for cancer treatment. In September 2023, it raised USD 311 mn in an IPO, selling 17.28 million shares at USD 18 per share on Nasdaq.

4Funding rounds

21Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in